Organization: Lady Davis Institute for Medical Research

Mimetogen Pharmaceuticals receives series B financing

Montreal-based Mimetogen Pharmaceuticals has closed a series B financing round to further develop its neurotrophin mimetics to treat dry eye and other degenerative ocular disorders. The financing is provided by Medwell Capital Inc, which is committing up to $2-million in the privately held, clinical-stage spin off from McGill Univ and Lady Davis Institute for Medical…

Mimetogen Pharmaceuticals receives series A financing

McGill Univ spinoff Mimetogen Pharmaceuticals Inc has received series A financing from a venture capital consortium led by Boston-based VIMAC Milestone Medica Fund. Also participating is original investor MSBi Capital, a seed and early-stage fund created to commercialize technologies from McGill, Univ of Sherbrooke and Bishop’s Univ. Mimetogen is currently developing therapeutic approaches for small…